Description:
This product is a potent inhibitor of Abl kinases and was developed for the treatment of chronic myeloid leukemia (CML). It works by blocking the activity of the Bcr-Abl fusion protein, which drives the growth of CML cells. Clinical trials have shown promising results, with high rates of complete remission and durable responses in patients with CML who were resistant or intolerant to previous treatments.
- Molecular Weight:698.15
- Purity:97%
Molecular Formula:
C37H37ClN5O5P
Canonical SMILES:
CN(C)P(=O)(OCC1CN(CC(O1)N2C=CC(=NC2=O)NC(=O)C3=CC=CC=C3)C(C4=CC=CC=C4)(C5=CC=CC=C5)C6=CC=CC=C6)Cl
InChI:
InChI=1S/C37H37ClN5O5P/c1-41(2)49(38,46)47-27-32-25-42(26-34(48-32)43-24-23-33(40-36(43)45)39-35(44)28-15-7-3-8-16-28)37(29-17-9-4-10-18-29,30-19-11-5-12-20-30)31-21-13-6-14-22-31/h3-24,32,34H,25-27H2,1-2H3,(H,39,40,44,45)/t32-,34+,49?/m0/s1
InChIKey:
RCQVHNTXMQCQLT-AUIRFOQBSA-N
Synonyms:
PMO-BzC Más detalles se encuentran
aquí